In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 54 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Effectiveness and cost-effectiveness of a novel cardiac rehabilitation program for obese patients with coronary artery disease or atrial fibrillation. Study protocol of the OPTICARE XL study

Session Poster Session 2

Speaker Madoka Sunamura

Event : ESC Preventive Cardiology (Formerly EuroPrevent) 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Coronary Artery Disease - Other
  • Session type : Poster Session

Authors : I Den Uijl (Rotterdam,NL), NCCW Tenbult-Van Limpt (Eindhoven/Veldhoven,NL), N Ter Hoeve (Rotterdam,NL), M Sunamura (Rotterdam,NL), JJ Kraal (Eindhoven/Veldhoven,NL), HMC Kemps (Eindhoven/Veldhoven,NL), HJG Van Den Berg-Emons (Rotterdam,NL)

I Den Uijl1 , NCCW Tenbult-Van Limpt2 , N Ter Hoeve1 , M Sunamura1 , JJ Kraal2 , HMC Kemps3 , HJG Van Den Berg-Emons4 , 1Capri Cardiac Rehabilitation - Rotterdam - Netherlands , 2Máxima Medical Centre, FLOW Centre for rehabilitation and prevention in chronic disease - Eindhoven/Veldhoven - Netherlands , 3Máxima Medical Centre, Department of Cardiology - Eindhoven/Veldhoven - Netherlands , 4Erasmus Medical Center, Department of Rehabilitation Medicine - Rotterdam - Netherlands ,

On behalf: OPTICARE XL

European Journal of Preventive Cardiology ( May 2018 ) 25 ( Supplement 1 ), 77

Introduction Obese patients with coronary artery disease (CAD) or atrial fibrillation (AF) currently participate in regular cardiac rehabilitation (CR) programs. However, effects of CR appear smaller than in non-obese patients, and are rarely sustained over time. Purpose We study the clinical- and cost-effectiveness of a new patient-oriented cardiac rehabilitation program, OPTICARE XL, especially developed for obese CAD and AF patients. Methods In this multicentre randomised controlled trial, 200 cardiac patients will be included. Participants will be randomized 1:1 to regular CR or an intervention group. In the first three months patients in the intervention group receive 20-24 exercise sessions in a group with other obese cardiac patients. In addition, they receive 12 interactive group sessions about healthy weight and four sessions about active lifestyle management. Furthermore, patients can participate in regular CR sessions such as psychosocial therapy and stress management. Between three months and one year, the intervention group receives an aftercare program comprising six follow-up meetings, and access to a mobile chat with a dietician, physical therapist and other participants. The control group receives regular CR for three months. The main endpoints are health-related quality of life and cost-effectiveness, secondary endpoints are physical fitness, body composition, other cardiac risk factors and physical activity levels, assessed at baseline, three months, nine months (control group), 12 months (intervention group) and 18 months after inclusion. Initiator in this study is Capri Cardiac Rehabilitation Rotterdam. This work received funding from the Dutch Organisation for Health Research and Development (ZonMw, Grant number 843001702). Results The first results are expected in 2019. Conclusion This study will provide insight in (cost-)effectiveness of a novel cardiac rehabilitation program for obese patients with coronary artery disease or atrial fibrillation. We expect that a tailored program for obese cardiac patients results in improved outcomes compared to regular CR.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are